1. Home
  2. IBP vs RYTM Comparison

IBP vs RYTM Comparison

Compare IBP & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Installed Building Products Inc.

IBP

Installed Building Products Inc.

HOLD

Current Price

$206.09

Market Cap

5.6B

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$104.91

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBP
RYTM
Founded
1977
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.8B
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
IBP
RYTM
Price
$206.09
$104.91
Analyst Decision
Hold
Strong Buy
Analyst Count
8
14
Target Price
$266.14
$131.14
AVG Volume (30 Days)
270.7K
432.7K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
1.18%
N/A
EPS Growth
6.70
28.34
EPS
3.71
N/A
Revenue
$2,970,800,000.00
N/A
Revenue This Year
$1.96
$55.34
Revenue Next Year
$4.32
$86.06
P/E Ratio
$56.75
N/A
Revenue Growth
1.00
N/A
52 Week Low
$193.11
$74.50
52 Week High
$349.00
$122.20

Technical Indicators

Market Signals
Indicator
IBP
RYTM
Relative Strength Index (RSI) 28.05 38.90
Support Level $195.46 $99.14
Resistance Level $229.34 $113.04
Average True Range (ATR) 9.12 4.02
MACD -4.84 -1.21
Stochastic Oscillator 0.58 19.49

Price Performance

Historical Comparison
IBP
RYTM

About IBP Installed Building Products Inc.

Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is derived from Installation segment.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: